Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

ntly completed patient enrollment for its Phase 3 clinical trials, HCVerso®1 and 2 (NCT01732796, NCT01728324), which investigate the efficacy and safety of the investigational compounds, faldaprevir and deleobuvir, in combination with ribavirin. These trials evaluate genotype-1b HCV patients, including difficult-to-treat populations such as those who are ineligible for interferon and those with liver disease including cirrhosis. 

Faldaprevir, deleobuvir, and PPI-668 are investigational compounds and not approved. Their safety and efficacy have not been fully established.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso™ (NCT01343888, NCT01297270, NCT01358864, NCT01399619) and HCVerso®.

Faldaprevir (BI 201335) is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso™ is a multi-study Phase 3 trial program that evaluates faldaprevir combined with
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... - The unique breadth ... at ESC Congress 2015 provide s ... of manag ing AF in everyday clinical practice across ... first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial ... most frequent major event in more than 17,000 newly diagnosed AF patients, far ...
(Date:9/1/2015)... Sept. 1, 2015  Based on its ... market, Frost & Sullivan recognizes Pie Medical ... & Sullivan Award for Technology Leadership. ... designed innovative and easy-to-use imaging solutions—its CAAS ... reproducible quantitative results for cardiovascular diagnosis and ...
(Date:9/1/2015)... 2015  Abbott (NYSE: ABT ) announced today positive ... trial comparing the safety and effectiveness of Abbott,s fully ... Abbott,s market-leading, permanent drug eluting stent. The trial was ... and enrolled 400 people with coronary artery disease, ... will be featured at a late-breaking session today at ...
Breaking Medicine Technology:Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... Masimo (Nasdaq: MASI ) announced ... Welfare (MHLW) regulatory clearance of its noninvasive and ... the Masimo rainbow SET® platform.  Representing a breakthrough ... hemoglobin level in real-time, SpHb tracks and trends ...
... As US doctors consider the switch from paper charts to ... have teamed up to provide an absolutely free EMR ... only ad-supported EMR platform for medical providers in a sector ... for a five provider practice in the first year. Since ...
Cached Medicine Technology:Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 2Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 3Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 4Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 2Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 3Can an Ad-Supported EMR Fuel Healthcare's Technology Revolution? 4
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... ... 01, 2015 , ... Spinal fusion surgery – which connects ... long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as traditional ... muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, according ...
(Date:8/31/2015)... ... August 31, 2015 , ... Cosmetic Town Journal is an ... to have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform ... always ready to help. , It is clear that the Cosmetic Town aesthetic ...
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – ... teamed up with fellow South Walton property management company, 360 Blue, in ... in remote parts of the world. The two companies will collect any unopened food ...
(Date:8/31/2015)... ... August 31, 2015 , ... India ... new “ InstantQuote ” tool, which summarizes all available plans, plan maximums, pre-existing ... tool is designed to help India Network members make an informed decision regarding ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... adults who consume one to seven alcoholic beverages a week may ... do not drink, according to a latest study. // ... University of Florida, showed that when compared with never or occasional ... cent lower risk of death over all and an almost 30 ...
... that Gardasil, which is a vaccine by Merck, for the ... ,The drug Gardasil, which is reported to offer ... onset of cervical cancer, making it a very practical option ... have indicated that there is a slow uptake for the ...
... (CFIA) has issued a warning for those who are allergic ... Flavor// 3 in 1 Coffee mix brand. This product is ... have not disclosed on the label. ,Though there ... of consumption of this product, yet it could cause a ...
... Health and Safety Executive (HSE) says that recycling boxes are ... In a new report, the HSE// said that any such ... by countless households in the country, could become too heavy ... ,These boxes also exceed the recommended weight limit. The ...
... releases a dose of nicotine and is one of ... quit smoking.// ,The federal government has announced ... The lozenges are to join nicotine patches, gums and ... was taken because the government said that the prescription ...
... avian influenza has clearly demonstrated that the New Zealand ... to Poultry Industry Association executive director Michael Brooks. ... of highly pathogenic notifiable avian influenza as well as ... samples from thousands of poultry meat birds. ...
Cached Medicine News:
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: